Globally, teams in risk, procurement, and compliance are under pressure to manage geopolitical risks and business risks. Third-party risks are impacted by the complexity of domestic and international businesses, as well as complex and diverse regulations. It is crucial that companies proactively manage third-party relationships. This cutting-edge platform, powered by D&B Data Cloud's 520M+ Global Business Records with 2B+ annual updates for third-party risks, is an AI-powered solution that mitigates and monitors counterparty risk on a continual basis. D&B Risk Analytics uses best-in class risk data, including alerts for high-risk purchases and match points of more than a billion. This helps to drive informed decisions. Intelligent workflows allow for quick and thorough screening. Receive alerts on key business indicators.
Learn more
IUX is a trading platform offering access to more than 250 financial instruments, including forex, stocks, indices, cryptocurrencies, commodities, and thematic indices. It provides competitive spreads, with spreads from 0.0 pips available on selected instruments and account types, while trading conditions may vary depending on market conditions. The platform also offers commission-free trading on selected products and account types, as well as fast order execution supported by institutional-grade liquidity, although execution speed may vary depending on factors such as market volatility, internet connection, and order size.
Traders can access markets through multiple platforms, including the IUX App Trade and MetaTrader 5, available on desktop and mobile devices. The platform offers pricing transparency, no requotes, and no trade restrictions, supporting a smooth trading experience. IUX Markets also provides market analytics, an economic calendar, and margin and spread calculators to assist traders in making informed decisions.
Regulated by the Financial Services Commission of Mauritius, the FSA of Saint Vincent and the Grenadines, the FSCA of South Africa, and ASIC in Australia, the platform places importance on security and compliance, and follows PCI DSS standards to help protect customer funds and data.
Learn more
XLNet
XLNet introduces an innovative approach to unsupervised language representation learning by utilizing a unique generalized permutation language modeling objective. Furthermore, it leverages the Transformer-XL architecture, which proves to be highly effective in handling language tasks that require processing of extended contexts. As a result, XLNet sets new benchmarks with its state-of-the-art (SOTA) performance across multiple downstream language applications, such as question answering, natural language inference, sentiment analysis, and document ranking. This makes XLNet a significant advancement in the field of natural language processing.
Learn more
IXRS®3
Our leading solution for managing patient randomization and trial supplies is available in various formats, making it the most adaptable and customizable Interactive Response Technology on the market. Whether you're conducting Phase I or Phase IV trials, and regardless of whether your study design is straightforward or involves complex adaptive methodologies, IXRS®3 is equipped to handle any combination of study goals. Additionally, you will benefit from a dedicated team of biostatisticians and integration specialists who are available around the clock to provide support. The functions intended for site users streamline processes that are typically vulnerable to human mistakes, allowing them to correct data independently without needing to contact a Help Desk or worry about compliance issues. Instead of sifting through numerous pages of specifications and legal jargon, users can access clear visual tools that enhance understanding. Furthermore, you can monitor and respond to each development stage of the software build, which helps to prevent unexpected issues during delivery, ensuring a smoother trial experience. This comprehensive approach not only facilitates efficiency but also empowers users with greater control over their trial processes.
Learn more